A Phase III Study of Venetoclax plus Acalabrutinib or Obinutuzumab in People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Share

Full Title

MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Purpose

The purpose of this study is to find out whether the combination of venetoclax and acalabrutinib is a safe and effective treatment for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) compared to the standard approach of venetoclax and obinutuzumab.

Acalabrutinib blocks a protein called BTK, which helps lymphoma cells multiply and survive. Venetoclax blocks Bcl-2, a protein that helps cancer cells survive and resist the effects of cancer treatments. Obinutuzumab targets a protein called CD20 found on the surface of B cells, the white blood cells affected by CLL. When obinutuzumab attaches to CD20, it helps the immune system recognize and attack cancerous B cells.

Participants in this study will be randomly assigned to receive either venetoclax plus acalabrutinib or venetoclax plus obinutuzumab. Venetoclax and acalabrutinib are taken orally (by mouth) and obinutuzumab is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have CLL or SLL that has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

Contact

For more information about this study and to ask about eligibility, please contact the office of Dr. Anthony Mato at 646-608-3748.

Protocol

22-262

Phase

III

Disease Status

Newly Diagnosed

Investigator

Co-Investigators